{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:49Z","timestamp":1790014849863,"version":"4.0.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) is shown to cause substantial morbidity, hospitalization, and mortality in infants and older adults. Population-level modeling of RSV allows to estimate the full burden of disease and the potential epidemiological impact of novel prophylactics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We modeled the RSV epidemiology in the United States across all ages using a deterministic compartmental transmission model. Population-level symptomatic RSV acute respiratory tract infection (ARI) cases were projected across different natural history scenarios with and without vaccination of adults aged \u226560 years. The impact of vaccine efficacy against ARIs, infectiousness and vaccine coverage on ARI incidence were assessed. The impact on medical attendance, hospitalization, complications, death, and other outcomes was also derived.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Without a vaccine, we project 17.5\u201322.6 million symptomatic RSV ARI cases annually in adults aged \u226518 years in the US, with 3.6\u20134.8 million\/year occurring in adults aged \u226560 years. Modeling indicates that up to 2.0 million symptomatic RSV-ARI cases could be prevented annually in \u226560-year-olds with a hypothetical vaccine (70% vaccine efficacy against symptomatic ARI and 60% vaccine coverage) and that up to 0.69 million\/year could be prevented in the nonvaccinated population, assuming 50% vaccine impact on infectiousness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The model provides estimated burden of RSV in the US across all age groups, with substantial burden projected specifically in older adults. Vaccination of adults aged \u226560 years could significantly reduce the burden of disease in this population, with additional indirect effect in adults aged &amp;lt;60 years due to reduced transmissibility.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad161","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T19:42:43Z","timestamp":1679514163000},"page":"480-489","source":"Crossref","is-referenced-by-count":21,"title":["Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model"],"prefix":"10.1093","volume":"77","author":[{"given":"T","family":"Van Effelterre","sequence":"first","affiliation":[{"name":"Janssen Pharmaceutica N.V. , Global Commercial Strategy Organization, Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-0637","authenticated-orcid":false,"given":"N","family":"Hens","sequence":"additional","affiliation":[{"name":"I-BioStat, Data Science Institute, Hasselt University , Hasselt , Belgium"},{"name":"Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"White","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford , Oxford, Oxfordshire , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gravenstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University , Providence, Rhode Island , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A R","family":"Bastian","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Buyukkaramikli","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica N.V. , Global Commercial Strategy Organization, Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Y","family":"Cheng","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica N.V. , Global Commercial Strategy Organization, Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hartnett","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Krishnarajah","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Weber","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Pharma GmbH , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Hernandez","family":"Pastor","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica N.V., Market Access , Global Commercial Strategy Organization, Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2023081421091323700_ciad161-B1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Lower Respiratory Infections Collaborators","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023081421091323700_ciad161-B2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","article-title":"Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States","volume":"40","author":"Herring","year":"2022","journal-title":"Vaccine"},{"key":"2023081421091323700_ciad161-B3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2023081421091323700_ciad161-B4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12889-017-4177-z","article-title":"Estimates of hospitalization attributable to influenza and RSV in the US during 1997\u20132009, by age and risk status","volume":"17","author":"Matias","year":"2017","journal-title":"BMC Public Health"},{"key":"2023081421091323700_ciad161-B5","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999\u20132018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023081421091323700_ciad161-B6","doi-asserted-by":"crossref","first-page":"010425","DOI":"10.7189\/jogh.09.010425","article-title":"A landscape review of the published research output relating to respiratory syncytial virus (RSV) in North & Central America and Europe between 2011\u20132015","volume":"9","author":"Kirolos","year":"2019","journal-title":"J Glob Health"},{"key":"2023081421091323700_ciad161-B7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","article-title":"Respiratory syncytial virus infection in older adults: an under-recognized problem","volume":"32","author":"Branche","year":"2015","journal-title":"Drugs Aging"},{"key":"2023081421091323700_ciad161-B8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.ajem.2017.06.022","article-title":"RSV in adult ED patients: do emergency providers consider RSV as an admission diagnosis?","volume":"35","author":"Binder","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2023081421091323700_ciad161-B9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1386-6532(03)00002-7","article-title":"Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults","volume":"28","author":"Casiano-Col\u00f3n","year":"2003","journal-title":"J Clin Virol"},{"key":"2023081421091323700_ciad161-B10","first-page":"747","article-title":"The diagnosis of viral respiratory disease in older adults","volume":"50","author":"Talbot","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023081421091323700_ciad161-B11","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1128\/JCM.00698-11","article-title":"Current best practices for respiratory virus testing","volume":"49","author":"Ginocchio","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2023081421091323700_ciad161-B12","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023081421091323700_ciad161-B13","doi-asserted-by":"crossref","first-page":"13239","DOI":"10.1073\/pnas.1522597113","article-title":"Vaccination strategies against respiratory syncytial virus","volume":"113","author":"Yamin","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023081421091323700_ciad161-B14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/aje\/kws257","article-title":"The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease","volume":"176","author":"Ohuma","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2023081421091323700_ciad161-B15","doi-asserted-by":"crossref","first-page":"e0138018","DOI":"10.1371\/journal.pone.0138018","article-title":"Vaccine induced herd immunity for control of respiratory syncytial virus disease in a low-income country setting","volume":"10","author":"Kinyanjui","year":"2015","journal-title":"PLoS One"},{"key":"2023081421091323700_ciad161-B16","doi-asserted-by":"crossref","first-page":"100055","DOI":"10.1016\/j.jvacx.2020.100055","article-title":"Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting","volume":"4","author":"Kinyanjui","year":"2020","journal-title":"Vaccine X"},{"key":"2023081421091323700_ciad161-B17","doi-asserted-by":"crossref","first-page":"e1004591","DOI":"10.1371\/journal.ppat.1004591","article-title":"Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States","volume":"11","author":"Pitzer","year":"2015","journal-title":"PLoS Pathog"},{"key":"2023081421091323700_ciad161-B18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.vaccine.2016.10.073","article-title":"Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: a consensus modelling approach","volume":"35","author":"Pan-Ngum","year":"2017","journal-title":"Vaccine"},{"key":"2023081421091323700_ciad161-B19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","article-title":"Potential impact of nirsevimab on RSV transmission and medically attended lower respiratory tract illness caused by RSV: a disease transmission model","volume":"11","author":"Voirin","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2023081421091323700_ciad161-B20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"Hodgson","year":"2020","journal-title":"BMC Med"},{"key":"2023081421091323700_ciad161-B21","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"2023081421091323700_ciad161-B22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/infdis\/jiab315","article-title":"Respiratory syncytial virus (RSV)\u2013specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants","volume":"225","author":"Koivisto","year":"2022","journal-title":"J Infect Dis"},{"key":"2023081421091323700_ciad161-B23","doi-asserted-by":"crossref","first-page":"e1009098","DOI":"10.1371\/journal.pcbi.1009098","article-title":"Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era","volume":"17","author":"Prem","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2023081421091323700_ciad161-B24","doi-asserted-by":"crossref","first-page":"S812","DOI":"10.1093\/ofid\/ofab466.1650","article-title":"LB14. Efficacy and immunogenicity of an Ad26.RSV.preF-based vaccine in the prevention of RT-PCR-confirmed RSV-mediated lower respiratory tract disease in adults aged \u226565 years: a randomized, placebo-controlled, phase 2b study","volume":"8","author":"Falsey","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023081421091323700_ciad161-B25","author":"GSK"},{"key":"2023081421091323700_ciad161-B26","author":"Gurtman"},{"key":"2023081421091323700_ciad161-B27","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study","volume":"226","author":"Sadoff","year":"2022","journal-title":"J Infect Dis"},{"key":"2023081421091323700_ciad161-B28","author":"Falsey"},{"key":"2023081421091323700_ciad161-B29"},{"key":"2023081421091323700_ciad161-B30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJM197903083001004","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children","volume":"300","author":"Henderson","year":"1979","journal-title":"N Engl J Med"},{"key":"2023081421091323700_ciad161-B31","doi-asserted-by":"crossref","first-page":"100156","DOI":"10.1016\/j.ajpc.2021.100156","article-title":"S. population at increased risk of severe illness from COVID-19","volume":"6","author":"Ajufo","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"2023081421091323700_ciad161-B32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jiv263","article-title":"Frequent asymptomatic respiratory syncytial virus infections during an epidemic in a rural Kenyan household cohort","volume":"212","author":"Munywoki","year":"2015","journal-title":"J Infect Dis"},{"key":"2023081421091323700_ciad161-B33"},{"key":"2023081421091323700_ciad161-B34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"key":"2023081421091323700_ciad161-B35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/infdis\/jiaa331","article-title":"Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older","volume":"223","author":"Jackson","year":"2021","journal-title":"J Infect Dis"},{"key":"2023081421091323700_ciad161-B36","doi-asserted-by":"crossref","first-page":"ofy316","DOI":"10.1093\/ofid\/ofy316","article-title":"Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults \u226560 years old","volume":"5","author":"Belongia","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023081421091323700_ciad161-B37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023081421091323700_ciad161-B38","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","article-title":"Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"key":"2023081421091323700_ciad161-B39","first-page":"CD004876","article-title":"Vaccines for preventing influenza in the elderly","volume":"2018","author":"Demicheli","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023081421091323700_ciad161-B40","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1016\/j.vaccine.2017.08.028","article-title":"Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: current and future implications","volume":"35","author":"McLaughlin","year":"2017","journal-title":"Vaccine"},{"key":"2023081421091323700_ciad161-B41","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1093\/infdis\/jiaa424","article-title":"Estimating transmission parameters for respiratory syncytial virus and predicting the impact of maternal and pediatric vaccination","volume":"222","author":"van Boven","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad161\/49599275\/ciad161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/3\/480\/51112038\/ciad161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/3\/480\/51112038\/ciad161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T21:10:33Z","timestamp":1692047433000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/3\/480\/7084151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad161","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,23]]}}}